Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
Topics in Public Health: Ending the HIV Epidemic (EHE) Initiative: Progress and Opportunities
October 18, 2024
Webinar

Activity Coordinators:
Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov),  Jessica Voqui (Jessica.Voqui@fda.hhs.gov),  Mavis Darkwah (Mavis.Darkwah@fda.hhs.gov),  Ruby Leong (Ruby.Leong@fda.hhs.gov)
Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description
The Ending the HIV Epidemic (EHE) initiative was launched in 2019 with a goal of reducing the number of new HIV infections in the U.S. by 90%, prioritizing additional resources for 5O jurisdictions that account for 50% of the new HIV infections and 7 states with substantial rural burden of HIV.

The plan leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response by coordinating the highly successful programs, resources, and infrastructure of many HHS agencies and offices. EHE is currently in the 5th year of program implementation and the most recent (2022) HIV Surveillance data demonstrate significant progress despite disparities in program outcomes.

The presentation will provide an opportunity to learn about the impact of the EHE initiative, identify some lessons learned from community engagement, and review strategies to optimize the outcomes of the EHE initiative.
References
  • Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019;321(9):844–845. doi:10.1001/jama.2019.1343
  • Brett P. Giroir, “The Time Is Now to End the HIV Epidemic”, American Journal of Public Health 110, no. 1 (January 1, 2020): pp. 22-24. doi.org/10.2105/AJPH.2019.305380
  • Centers for Disease Control and Prevention. HIV Surveillance Data Tables: Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data): National HIV Surveillance System Data Reported through June 2023; and Preexposure Prophylaxis (PrEP) Data Reported through March 2023. https://stacks.cdc.gov/view/cdc/149086. Published October 2023
  • Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2018–2022. https://stacks.cdc.gov/view/cdc/156513. Published May 2024.
  • Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019;321(9):844–845. doi:10.1001/jama.2019.1343
  • Brett P. Giroir, “The Time Is Now to End the HIV Epidemic”, American Journal of Public Health 110, no. 1 (January 1, 2020): pp. 22-24. doi.org/10.2105/AJPH.2019.305380
  • Centers for Disease Control and Prevention. HIV Surveillance Data Tables: Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (Preliminary Data): National HIV Surveillance System Data Reported through June 2023; and Preexposure Prophylaxis (PrEP) Data Reported through March 2023. https://stacks.cdc.gov/view/cdc/149086. Published October 2023
  • Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2018–2022. https://stacks.cdc.gov/view/cdc/156513. Published May 2024.
Series Objectives
  • Increase awareness of current topics in public health
  • Help improve patient/public health outcomes
  • Help participants modify their practice within their job or deployments
Learning Objectives After completion of this activity, the participant will be able to:
  • Review the key strategies to advance EHE in the U.S.
  • Analyze the impact of the EHE interventions in the U.S.
  • Analyze findings from community engagement in southern states.
  • Discuss lessons learned and innovations to optimize the EHE initiative.
Target Audience
This activity is intended for physicians, pharmacists, and nurses.
Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Agenda

Lecture 1 October 18, 2024
Time Topic Speaker
2:00 - 3:00 PM EDT Ending the HIV Epidemic (EHE) Initiative: Progress and Opportunities Adeoye Oguntomilade, PhD
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-018-L99-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor®. If you do not see your credit reflected on CPE Monitor®* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov.
*CPE Monitor® sets a strict 60-day limit on uploading credits.

Disclosure

Faculty
  • Oguntomilade, Adeoye, PhD, National Ending the HIV Epidemic Coordination Lead, HHS/OASH - nothing to disclose

Planning Committee
  • Adejuwon, Adesola, PharmD, MBA, Regulatory Review Officer, FDA - nothing to disclose
  • Adeyemo, Folaremi, PharmD, Regulatory Health Project Manager, FDA - nothing to disclose
  • Birch-Smith, Postelle, PharmD, Lead CSO, FDA - nothing to disclose
  • Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
  • Camilli, Sara, PharmD, BCPS, Associate Director, FDA/CDER/OSE/DPV II - nothing to disclose
  • Gonzalez-Mercado, Carlos, PharmD, MA, Emergency Coordinator, FDA - nothing to disclose
  • Herber, Kari, RN, Regional Program Manager, Department of Homeland Security - nothing to disclose
  • Janusziewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OUDLC - nothing to disclose
  • Radden, Erica, MD, Medical Officer, USPHS/DHS/USCG - nothing to disclose
  • Zepeda, Josephine, PharmD, BCPP, Clinical Psychiatric Pharmacist, USPHS - nothing to disclose

CE Consultation and Accreditation Team
  • Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.